Somerset Lifesciences Inc. Agrees to Pay $4M to Resolve Allegations of Causing Medicare to Pay Claims for its Mislabeled Generic Drug

The record

Publisher

U.S. Department of Justice

Source

U.S. Department of Justice

Kind

Release

Jurisdiction

United States

Topics

Enforcement

Importance

Notable, the middle of three tiers Kresmion sets by fixed rules from the source's own fields

Published (source time)

2026-10-16 12:00 UTC

First seen on Kresmion

2026-10-19 02:47 UTC, 2 days after publication

The original

Link checked 2026-10-27: available.

Source: U.S. Department of Justice. U.S. Government work.

The publisher's summary

Somerset Lifesciences Inc. (Somerset) has agreed to pay $4 million to resolve common law claims for causing Medicare Part D (Medicare) to pay for its prescription-only (Rx-only) generic drug Olopatadine when it was no longer eligible for Medicare coverage. Medicare does not cover drugs that can be purchased by retail customers over-the-counter (OTC) without a prescription. In 2020, the brand name version of Olopatadine switched from Rx-only to OTC, and Somerset was required to change Olopatadine’s label from Rx-only to OTC as well. Instead, Somerset continued to label and sell Olopatadine as Rx-only and caused Medicare to wrongfully pay claims for an OTC drug.

The publisher's words, as published.